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Abstract 
The objective of present work was to develop a novel 
liposomes-based drug delivery system for a lipophilic non-
steroidal anti-inflammatory drug, piroxicam. The system was 
prepared using proliposomes method and optimised for 
different preparation parameters including type of 
proliposomes, concentration of drug, duration of hydration and 
type of particle size reduction treatment used. All prepared 
liposomal samples were extensively characterized for their 
drug-entrapment and size profile using various in-vitro 
techniques. Present work showed that the most optimum 
formulation (Pro-lipoTM Duo; 12mg piroxicam per gram Pro-
lipoTM; 10 hours hydration time) produced highest amount of 
actual drug been entrapped in liposomes (800.4 mg/g Pro-
lipoTM) with a satisfactory entrapment efficiency of 15.36%. 
This formulation had also produced liposomal samples with a 
homogenous (polydispersity index = 0.45) and small particle 
size (359.95nm). Extrusion technique was found to cause 
significant reduction in drug-entrapment and size profile of 
drug-loaded liposomes. A 4-weeks storage study showed that 
drug-entrapment and size profile of liposomal samples were 
stable in both refrigerated and room temperature. Electron 
microscopy revealed that prepared liposomal samples were 
spherical-shaped and showed concentric lamellae. In 
conclusion, present work successfully demonstrated a simple, 
reproducible and practical method of preparation for 
liposomes-encapsulated piroxicam. 
 
Keywords: Proliposomes; Liposomes; Piroxicam; 
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Introduction 
Liposomes are microscopic spherical vesicles 
composed of lipid bilayers which formed by 
phospholipids dispersed in water [1]. Due to their 
high degree of biocompatibility and effectiveness 
in the modulation of drug release properties [2], 
liposomes have been used in many drug delivery 
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research as vehicles to incorporate assortment of 
active agents [3]. Literature has also showed that 
liposomes-entrapped drugs exhibit improved 
therapeutic indices and superior pharmacological 
properties than those observed with conventional 
formulations [4].  
An attempt has been made in present work to 
develop a practical liposomes-based drug 
delivery system for piroxicam (4-hydroxy-2-
methyl-N-(pyridine-2-yl)-2H-1,2-benzothiazine-
3-carboxamide-1,2-dioxide). Piroxicam, an 
oxicam derivative, is a well-known non-steroidal 
anti-inflammatory drug discovered by Pfizer 
Laboratories [5,6]. Pharmacokinetic study has 
demonstrated that the hydrophobic piroxicam has 
a slow absorption via oral route, which resulted in 
low bioavailability of the drug and delayed the 
onset of its therapeutics effects [7]. Due to the 
potential modification of drug’s bioavailability 
and therapeutic index using liposomal 
technology, the strategy to entrap piroxicam in 
liposomes is therefore deemed important in 
pharmaceutical field [8,9]. 
Over the years, numerous techniques and 
procedures have been described to prepare 
liposome-encapsulated drugs with different sizes 
and characteristics. Most of the preparation 
methods such as reverse-phase evaporation, ether 
injection and freeze-thaw method are tedious in 
nature and require long preparation time [10]. In 
current study, the proliposomes method, which 
based on the conversion of initial concentrated 
ethanolic solutions of phospholipids into 
liposomes dispersion by dilution under strictly 
controlled conditions [11], is used for rapid 
production of blank and piroxicam-loaded 
liposomes. This relatively simpler technique has 
been reported for its suitable to encapsulate drugs 
of various water and alcohol solubility with high 
entrapment efficacy [12].  
A number of factors, especially parameters used 
in the preparation procedures, have also been 
known to affect the quality of the liposomal 
samples [10,13,14]. In this paper, we present the 
results on the entrapment of piroxicam into 
liposomes. The formulation method and 
preparation procedures were optimized for 
parameters and properties that were deemed 
important in order to produce suitable drug-
loaded liposomal samples with satisfactory 
qualities of drug loading and size profile as well 
as potential for in-vivo performance.  
 
Materials and methods 
Materials  
Two commercial preparations of proliposomes, 
namely Pro-lipoTM Duo and Pro-lipoTM C (Lucas 
Meyer, France), were used. Pro-lipoTM Duo and 
C contained 50% and 40% unsaturated soybean 
phosphatidylcholine respectively which 
suspended in hydrophilic medium consisted of 
glycerol and ethanol. Piroxicam, 
dimethylsulfoxide and Triton X-100 were 
purchased from Sigma (USA). Acetonitrile and 
sodium dihydrogen phosphate 1-hydrate were 
originated from Merck (Germany). Hydrochloric 
acid was purchased from J.T. Baker (Thailand). 
All solvents and chemicals used were of 
analytical or HPLC grade. Water used in all 
present work was purified and deionized by 
Direct-QTM 3 water purification system 
(Millipore, France). 
 
Proliposomes, drug concentration and 
hydration time studies 
Liposomal samples preparation 
Piroxicam-loaded and blank liposomes were 
prepared in accordance to the manufacturer’s 
instructions with some modifications. All 
formulations, distinctive by different type of 
proliposomes, drug concentration and/or duration 
of hydration time used during preparation 
process, were produced in three batches 
respectively. Briefly, a stock piroxicam solution 
(60 mg/ml) was prepared initially by completely 
dissolving pre-determined amount of the drug in 
dimethylsulfoxide. These stock drug solutions 
were prepared freshly daily and protected from 
direct light. Next, 400 µl drug solution with 
known concentration was added gradually into 2g 
proliposomes (Pro-lipoTM Duo or C) in a beaker 
with moderate stirring (±100 rpm) for 60 
minutes. The blank liposomes were prepared 
according to the same procedure except 
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dimethylsulfoxide was used instead of drug 
solution. The mixture was then hydrated with 
3.6ml distilled water which was added gradually 
to form a concentrated liposomal suspension. 
These liposomal suspensions was stirred 
continuously for a pre-determined period of 
stirring (hydration) time before further diluted 
with 10ml distilled water with continuous stirring 
for another 30 minutes.  Preparation of all 
liposomal samples was carried out at room 
temperature.  
 
Drug entrapment analysis 
The amount of piroxicam successfully been 
entrapped into liposomes were quantified using 
the following previously validated in-vitro 
techniques. For the analysis of each liposomal 
sample’s formulations, duplicate samples were 
prepared from all of the three individual batches 
(n=6).  
 
Instrumentation and chromatographic 
condition 
The HPLC system used consisted of a Jasco PU-
980 Intelligent HPLC pump, Rheodyne 7125 
(Cotati) sample injector fitted with 50 µl sample 
loop, Jasco UV-975 Intelligent UV/VI Detector 
and Hitachi D-2500 Chromato-Integrator. A 
Jones Chromatography Genesis C18 column 
(4µm, 150 x 4.6 mm I.D.), fitted with a refillable 
guard column packed with Perisorb® RP-18 (30-
40 µm, pellicular) powder, was used for the 
chromatographic separation. The mobile phase 
consisted of 0.02M sodium dihydrogen 
orthophosphate 1-hydrate and acetonitrile (53:47, 
v:v) adjusted to pH 3.2 using 5M hydrochloric 
acid, which delivered at a flow rate of 
1ml/minute. The detection wavelength was set at 
360 nm with a sensitivity range of 0.005 a.u.f.s. 
and the amount of piroxicam was quantified 
using peak area. Retention time for piroxicam 
was 5.3 min. 
 
Total piroxicam determination 
To determine the concentration of the total 
piroxicam in prepared liposomal samples, Triton 
X-100 (0.2% in final concentration) was added 
into the liposomes suspensions in order to lyse 
the liposomes structure and released all entrapped 
drug. The mixture was vortexed for 30 seconds 
(Barnstead/Thermolyne, USA) and diluted with 
mobile phase before quantified using the HPLC 
method described in previous section. 
 
Free undissolved piroxicam determination 
To determine the concentration of free 
undissolved drug, liposomal samples were first 
been centrifuged at 12800 G for 10 minutes 
(MiniSpin® plus, Eppendorf, Germany) to 
precipitate undissolved and unentrapped 
hydrophobic drug. The supernatant was then 
discarded and the remaining sediment was 
reconstituted with mobile phase before subjected 
to HPLC analysis.  
 
Free dissolved piroxicam determination 
Liposomal samples were ultracentrifugated at 
300,000G and 20ºC for 90 minutes using a TLA-
110 rotor in OptimaTM MAX-XP ultracentrifuge 
(Beckman Coulter, USA). The supernatant, 
which contained only dissolved drug (confirmed 
by the absence of appreciable liposomal particles 
using particle size analyzer), was then collected. 
This supernatant samples were diluted with 
mobile phase to appropriate concentration before 
subjected to HPLC analysis. 
 
Calculation formulas 
Actual amount of piroxicam been entrapped in 
liposomal samples were calculated by subtracting 
the amount of free drug (undissolved and 
dissolved form) from the total drug input. The 
drug entrapment efficiency was evaluated as 
percent of the total input drug entrapped in the 
liposomes. 
 
Total piroxicam – Free piroxicam 
Amount entrapped (µg/g Pro-lipoTM ) = ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯   
                      Total Pro-lipoTM used 
 
           Total piroxicam – Free piroxicam 
Percent entrapped (%) = ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯  X 100 
                               Total piroxicam 
 
Particle size analysis 
The size profile for all of the liposomal samples 
was determined by photon correlation 
spectroscopy technique using Zetasizer Nano S 
(Malvern Instrument, UK). The procedure for 
particle size analysis entailed dispersing 10µl of 
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liposomal samples with 500µl distilled water in a 
low volume disposable sizing cuvette. The 
particle size and size distribution were measured 
by the instrument as ZAve and polydispersity 
index (PDI) respectively. For each formulation, 
two measurements were taken on two separate 
samples from three individual bathes of 
liposomal samples. 
 
Size reduction study 
The optimized formulation (Pro-lipoTM Duo; 
12mg piroxicam per 1g Pro-lipoTM; 10 hours 
hydration time) which produced highest amount 
of entrapped drug in previous section was 
selected for this study. Three batches of 
liposomal samples were freshly prepared using 
the same formulation according to the same 
procedure described earlier. Each batch of 
liposomal samples were subjected to either 
extrusion (single pass through a double-stacked 
0.1µm polycarbonate membrane filter) using 
LiposoFastTM  mini-extruder (Avestin Inc, 
Canada) or ultra-sonication in 300W bath 
sonicator (Digital Pro heated ultrasonic cleaner, 
Huiyuan Int’l Commerce & Exhibition Co., 
China) for 60 minutes. The drug entrapment and 
size profile for all prepared samples were 
evaluated using same procedures outlined in 
previous sections. 
 
Storage study  
In this part of study, the physical stability of 
liposomal samples stored in different conditions 
was evaluated in respect to their drug entrapment 
and particle size profile using same in-vitro 
techniques described previously. Each of the 
three batches of freshly prepared liposomal 
samples (optimized formulation) was equally 
separated and placed in two different 
temperatures respectively, namely in refrigerated 
temperature (2C to 8C) and ambient room 
temperature (25C±2C). All samples were 
stored in air-tight test tubes away from direct 
light. Samples for analyses were withdrawn at 
definite time intervals throughout the 4-weeks 
storage study. 
Reproducibility testing 
Data obtained from six different batches of 
liposomal samples which prepared using the 
same formulation (Pro-lipoTM Duo; 12mg 
piroxicam per 1g Pro-lipoTM; 10 hours hydration 
time; no size reduction treatment) were used to 
investigate the reproducibility of drug entrapment 
and particle size profile. 
 
Transmission electron microscopy (TEM) 
Morphological and size examinations of freshly 
prepared blank, drug-loaded and extruded drug-
loaded liposomes were done using negative 
staining electron microscopy. A droplet of the 
spontaneously formed liposomal samples to be 
examined was placed onto a carbon-coated 
copper grid (400 mesh) for about 3 minutes in 
order to reach absorption equilibrium. The 
droplet was then wicked to dryness using pieces 
of filter paper before leaving the grid for another 
1 minute. Next, a droplet of the negative stain 
solution (2% uranyl acetate) was added to the 
surface of the grid. After 1 minute, the copper 
mesh grid was dried using pieces of filter paper 
and kept in a filter paper lined petri dish. The 
size, morphology and lamellarity of liposomes 
samples were then viewed on Philips CM12 
transmission electron microscope and 
photographed at an accelerating voltage of 80 kV. 
 
Statistical evaluations 
The results were presented as Mean ± S.E.M. All 
data were subjected to one-way analysis of 
variance (ANOVA) followed by Tukey’s 
multiple comparison test among groups, and 
Student’s t-test for comparison between two 
groups. P values less than 0.05 (P<0.05) were 
taken as the limit of significance. All statistical 
analyses were carried out using SPSS v16.0 
(SPSS Inc., Chicago). 
 
Results and discussion 
Proliposomes, drug concentration and 
hydration time studies 
Drug entrapment and particle size profile 
Lipophilic, bilayer-interacting NSAIDs such as 
piroxicam were naturally incorporated within the 
lipid bilayers of liposomes vesicle [15,16]. 
Reports in literature had showed that the 
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entrapment of drug molecules had been quite 
variable and the quality of final liposomal 
samples was largely depended on the type and 
compositions of lipid, buffer contents or 
preparation procedures used [10,17]. Data 
obtained from current study were presented in 
Table 1 and Table 2. 
In proliposomes study, both total amount of 
entrapped drug and the drug entrapment 
efficiency were higher for Pro-lipoTM Duo 
compared to Pro-lipoTM C, when same 
preparation process variable was used. However, 
statistically significant difference was only 
obtained for the actual amount of drug been 
entrapped. Better drug entrapment profile by Pro-
lipoTM Duo could be attributed to its higher 
phospholipids content, as suggested by Turanek 
et al. [12]. The availability of more phospholipids 
for drug interaction allowed higher amount of 
drug to be successfully entrapped.  Besides, 
presence of negative charges in Pro-lipoTM Duo 
tended to increase the spacing between 
successive phospholipids bilayers [10,18]. Thus, 
the capacity for drug entrapment would be 
increased compared to neutral multilamellar 
vesicles formed using Pro-lipoTM C. On the other 
Table 1: Drug entrapment profile when different type of Pro-lipoTM, concentration of drug and duration of 
hydration were employed (n=6) 
 
Amount entrapped (µg/g prolipo) Percent entrapped (%) Type of 
Pro-lipoTM 
Concentration 
of piroxicam 
(mg/g Pro-
lipoTM) 
1H 5H 10H 1H 5H used 10H 
4 387.5 ± 74.2 450.5 ± 85.2 441.9 ± 63.4 23.4 ± 4.7 24.6 ± 5.3 22.1 ± 2.3 
Duo 8 415.2 ± 99.9 461.1± 125.8 501.4± 59.8 11.8± 2.8 12.8± 3.2 14.3± 1.5 
12 728.7± 41.9 745.1± 65.8 782.0± 63.9 14.1± 0.9 13.5± 0.9 13.9± 0.9 
4 344.8± 110.0 427.9± 63.6 512.9± 92.6 17.1± 3.8 23.8± 3.7 25.8± 3.4 
8 390.2± 139.6 424.1± 97.8 499.0± 91.8 9.7± 3.0 11.8± 2.8 13.3± 2.3 C 
12 490.0± 85.1 498.8± 79.2 549.5± 136.1 8.7± 1.4 8.8± 1.2 9.3± 2.0 
 
Table 2: Particle size profile when different type of Pro-lipoTM, concentration of drug and duration of hydration 
were employed (n=12) 
Particle size (nm) PDI Type of 
Pro-lipoTM 
used 
Concentration 
of piroxicam 
(mg/g Pro-
lipoTM) 
1H 5H 10H 1H 5H 10H 
0 389.6± 3.6 398.0± 8.8 352.3± 7.9 0.483± 0.008 0.450± 0.009 0.453± 0.007 
4 372.2± 4.1 365.6± 9.9 352.6± 7.2 0.471± 0.002 0.449± 0.008 0.443± 0.010 
Duo 8 352.2± 9.7 343.9± 12.1 337.6± 7.8 0.456± 0.010 0.434± 0.136 0.448± 0.010 
12 355.9± 8.0 344.2± 7.0 345.6± 11.0 0.454± 0.012 0.444± 0.006 0.443± 0.011 
0 303.0± 5.2 293.3± 10.0 244.5± 6.5 0.429± 0.007 0.424± 0.005 0.405± 0.006 
4 301.2± 12.9 279.5± 0.6 248.7± 5.8 0.449± 0.137 0.427± 0.004 0.409± 0.006 
8 296.5± 11.4 272.2± 9.0 238.4± 9.4 0.425± 0.178 0.417± 0.107 0.388± 0.110 
C 
12 291.9± 11.4 258.4± 2.9 235.4± 3.5 0.417± 0.024 0.382± 0.005 0.404± 0.012 
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hand, liposomes formed using Pro-lipoTM Duo 
was significantly bigger in size and size 
distribution. This discrepancy could also be 
attributed by the differences of phospholipids and 
hydrophilic medium content in proliposomes. 
Pro-lipoTM Duo, which was more viscous than 
Pro-lipoTM C due its content, would had subjected 
to relatively less vigorous stirring force 
throughout the hydration period when similar 
stirring speed were used in preparation of both 
samples. As a result, the produced liposomes 
were comparatively less homogenous and bigger 
in size.  
In the drug concentration study, data obtained 
showed that the actual amount of drug 
successfully been entrapped increased 
significantly when higher concentration of 
piroxicam solution were used during liposomes 
preparation. On the contrary, increment of drug 
concentration produced significantly smaller and 
more homogenous liposomal samples. These 
phenomenons could be due to the increment of 
materials interaction and drug incorporation into 
vesicles when higher amount of lipophilic 
piroxicam was added into the lipidic 
proliposomes mixture. This was supported by the 
fact that Pro-lipoTM Duo, which contained higher 
amount of phospholipids, showed higher 
magnitude of increment in entrapment capacity 
compared to Pro-lipoTM C. As the amount of drug 
incorporated within the phospholipid bilayers 
increased, the bonds that holding successive 
bilayers decreased. In turn, the vesicle had looser 
packing which caused liposomes tend to have a 
smaller particle size [19]. Regretfully, drug 
entrapment efficiency decreased significantly as 
higher drug concentration was used. This trend 
suggested that the drug entrapment into lipid 
bilayers of liposomes were amount-limited, 
causing proportionally less increment on their 
successful drug entrapment rate compared to 
actual amount of drug used during sample 
preparations. Besides, decreased in the size of 
liposomes which in turn proportionally decreased 
the amount of lipid bilayers for entrapping drug 
could also resulted in reduction of their drug 
entrapment capacity.   
In hydration study, an interesting trend of 
increment in the actual amount of piroxicam-
loaded liposomes and percentage of entrapment 
efficiency were observed for both grade of Pro-
lipoTM when longer stirring (hydration) time used. 
Regretfully, these observed increments were 
statistically not significant in present study. 
Fresta et al. [20] had claimed that slow rate of 
hydration and gentle mixing was beneficial for 
the entrapment efficiency due to slow annealing 
of multilamellar vesicle, which allowed for a 
longer period of contact between all the 
liposomes bilayers and the drug aqueous solution. 
On the other hand, data obtained showed that 
longer hydration time resulted in significantly 
smaller particle size and narrower size 
distribution in both type of Pro-lipoTM. A 
combination of impingement, cavitation and 
shear force from the continuously stirring 
mechanism during samples preparation could 
have been responsible to reduce the size of 
suspended liposomes and yield a more 
homogenous sample.  
 
Applications for further studies 
One of the primary aims in current study was to 
determine the most suitable formulation which 
capable to use least amount of material 
(proliposomes) to encapsulate the largest amount 
of the model drug (piroxicam). Besides being 
cost effective, minimization of phospholipid 
content in liposomal drug formulation was 
important since lipids in high doses may be toxic 
and also cause non-linear/saturable 
pharmacokinetics [21]. On the other hand, 
smaller particle size had been reported to pose 
various advantageous characteristics including its 
effective interaction with cells, increased drug 
bioavailability in pathological area and longer 
circulation half life [21-23].  Thus, liposomal 
sample prepared using Pro-lipoTM Duo, 12mg 
piroxicam per gram Pro-lipoTM and 10 hours 
hydration time were deemed as the most optimum 
formulation which could produced highest 
amount of actual drug loaded into liposomes as 
well as exhibited homogenous and small particle 
size in nano range. 
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Size reduction study  
This study was an attempt to search for a 
practical size reduction method which produced 
smaller and more homogenous liposomal 
samples, without compromising their initial drug 
entrapment capacity and efficiency. Data 
obtained were presented in Table 3. Bath 
sonication, though was a relatively more 
convenient method, did not cause a significant 
trend of decrement in the entrapment and size 
profile for treated liposomal samples. Only the 
extrusion method resulted in statistically 
significant loss in drug entrapment capacity and 
efficiency as well as significant decrement in size 
and size distribution of liposomes. 
From the data and trends observed in this study, it 
could be concluded that the extrusion technique 
through polycarbonate membrane filter was a far 
superior size reduction method than the bath 
sonication technique. The impingement and shear 
forces created when forcing the liposomes 
through small pores of membrane filter could 
destroy the lamellar surface, allowing the 
formation of monodisperse vesicles [24]. 
Regretfully, extrusion of liposomes resulted in 
significant loss of the originally entrapped 
piroxicam, which was also manifested by the 
decrease in the entrapment efficiency. These 
marked reductions in drug entrapment capacity 
and efficiency could attribute to the lower 
entrapment volume (lipid bilayers) available for 
entrapping drug molecules. Similar findings had 
also been previously reported [10, 21, 25]. On the 
other hand, results showed that liposomes had a 
size larger than the pores through which they 
were extruded. This finding suggested the elastic 
deformation of the liposomes. A similar 
interpretation had also been suggested by Elhissi 
et al. [26]. 
 
Storage study  
Liposomes were known for their physical 
instability during storage due to potential drug 
leakage from vesicles and changes in the size of 
liposomes [21]. In present study, data obtained 
were presented in Table 4. The drug entrapment 
capacity and efficiency of prepared liposomal 
samples were found stable in both refrigerated 
Table 3: Drug entrapment and particle size profile before and after size reduction treatment  
 
Entrapment profile (n=6) Size profile (n=12) Size reduction 
treatment Amount entrapped (µg/g Pro-
lipoTM) 
Percent entrapped 
(%) Particle size (nm) PDI 
Without treatment 818.8 ± 124.1 16.9 ± 2.0 382.5 ± 3.0 0.463 ± 0.005 
Sonication 770.9 ± 95.9 14.6 ± 1.9 376.5 ± 2.0 0.451 ± 0.005 
Extrusion 335.8 ± 40.4 6.7 ± 0.8 135.6 ± 2.6 0.120  ± 0.007 
 
Table 4: Drug entrapment and particle size profile of liposomes kept under different storage conditions  
 
Refrigerated temperature (2C to 8C) Room temperature (25C±2C). 
Entrapment profile (n=6) Size profile (n=12) Entrapment profile (n=6) 
Size profile 
(n=12) 
W
e
e
k 
Amount 
entrapped 
(µg/g Pro-
lipoTM) 
Percent 
entrapped 
(%) 
Particle 
size 
(nm) 
PDI 
Amount 
entrapped 
(µg/g Pro-
lipoTM) 
Percent 
entrapped 
(%) 
Particle size 
(nm) PDI 
0 818.8± 124.1 16.9± 2.0 382.5± 3.0 0.463± 0.005 818.8± 124.1 16.9± 2.0 382.5± 3.0 0.463± 0.005 
1 761.3± 86.2 14.8± 1.6 380.7± 2.8 0.454± 0.005 762.7± 104.4 14.6± 2.0 381.8± 3.3 0.458± 0.006 
2 731.8± 100.4 14.6± 1.7 382.6± 2.1 0.463± 0.006 736.5± 115.9 14.9± 2.3 388.4± 3.2 0.443± 0.006 
3 746.0± 83.2 15.5± 1.5 377.7± 3.1 0.472± 0.013 757.1± 122.3 15.6± 2.3 387.6± 5.1 0.460± 0.007 
4 771.2± 79.7 15.3± 1.5 377.8± 1.9 0.457± 0.007 760.1± 97.4 14.9± 1.5 382.9± 3.0 0.473± 0.013 
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and room temperature. Although slight decrement 
pattern was observed in both storage 
temperatures throughout the duration of study, no 
statistically differences were found. These fairly 
high retention of drug (>90%) within the 
liposomes could be explained by great affinity of 
phospholipid bilayers towards the drug molecules 
as well as good structural integrity of the formed 
vesicles [2].  
On the other hand, particle size and PDI were 
also found to be stable in this study. No 
statistically differences were found on the effect 
of storage time to the size profile of these 
liposomal samples. However, liposomes kept in 
refrigerated temperature were found to have 
relatively slight decrement in particle size 
compared to those kept in the room temperature. 
This decrement of mean particle size could be 
due to the refrigerating and thawing mechanism 
when handling the samples, which resulted in the 
breaking up of larger sized liposomes. Damages 
could also caused by the crystallization of 
internal water, osmotic forces, dehydration and 
formation of amorphous material [25,27].   
Reproducibility testing 
In the context of this study, the measure of 
reproducibility was defined as the closeness 
between independent data obtained from each 
batch of samples which prepared at different time 
using identical materials, procedures and 
preparation conditions. A liposomal sample 
formulation, which was deemed to have the most 
desirable drug-entrapment and size profile for 
future works, was selected for current evaluation. 
The percent coefficient of variation (%CV) for all 
of the parameters tested was found to be less than 
15% (Table 5). Hence, the preparation of 
liposomal samples at different time using a same 
formulation and methodology was deemed to 
pose satisfactory reproducible physico-chemical 
values. 
 
Transmission electron microscope 
observations 
Direct visualization of liposomes in readily 
prepared liposomal samples using TEM 
technique revealed that different sizes of 
multilamellar vesicles were formed using current 
materials and preparation procedures (Figure 1). 
The blank and drug-loaded liposomes vesicles 
were observed to be spherical-shaped and showed 
concentric lamellae. Whereas, liposomal sample 
extruded through filter membrane produced 
clearly smaller oligolamellar liposomes, 
 
                 (A)                          (B)                      (C) 
Figure 1. TEM photograph of (A) blank liposomes; (B) piroxicam-loaded liposomes; (C) extruded piroxicam-
loaded liposomes. (Arrows: liposomes) 
 
Table 5: Reproducibility of piroxicam-loaded liposomes (n=6) 
 
Entrapment profile Size profile 
Batch name Amount entrapped 
(µg/g Pro-lipoTM) Percent entrapped (%) 
Particle size 
(nm) PDI 
Mean ± S.E.M 800.4 ± 48.9 15.4 ± 0.9 360.0 ± 14.4 0.454 ± 0.009 
CV (%) 14.964 14.825 9.775 4.830 
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indicating that lamellarity of liposomes was 
effectively reduced by the extrusion process. 
 
Conclusions  
In summary, findings in current studies 
conclusively demonstrated an optimized 
formulation and reproducible preparation of 
piroxicam-loaded liposomes which prepared 
using a simple proliposomes method. As a rule of 
thumb, preparation of piroxicam-loaded 
liposomes using Pro-lipoTM Duo with higher drug 
concentration at prolonged hydration period 
would able to yield smaller, more homogenous 
liposomes with improved drug entrapment 
capacity and satisfactory entrapment efficiency. 
Liposomes prepared were stably stored for at 
least 4 weeks. Furthermore, extrusion technique 
was demonstrated to be an effective size 
reduction method, whereas electron microscopy 
revealed sizes and lamellarity of prepared 
liposomal samples. 
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